

will not be disclosed except in accordance with procedures set forth in 40 CFR part 2.

2. *Tips for preparing your comments.* When submitting comments, remember to:

- i. Identify the document by docket ID number and other identifying information (subject heading, **Federal Register** date and page number).
- ii. Follow directions. The Agency may ask you to respond to specific questions or organize comments by referencing a Code of Federal Regulations (CFR) part or section number.
- iii. Explain why you agree or disagree; suggest alternatives and substitute language for your requested changes.
- iv. Describe any assumptions and provide any technical information and/or data that you used.
- v. If you estimate potential costs or burdens, explain how you arrived at your estimate in sufficient detail to allow for it to be reproduced.
- vi. Provide specific examples to illustrate your concerns and suggest alternatives.
- vii. Explain your views as clearly as possible, avoiding the use of profanity or personal threats.
- viii. Make sure to submit your comments by the comment period deadline identified.

3. *Environmental justice.* EPA seeks to achieve environmental justice, the fair treatment and meaningful involvement of any group, including minority and/or low income populations, in the development, implementation, and enforcement of environmental laws, regulations, and policies. To help address potential environmental justice issues, the Agency seeks information on any groups or segments of the population who, as a result of their location, cultural practices, or other factors, may have atypical or disproportionately high and adverse human health impacts or environmental effects from exposure to the pesticide(s) discussed in this document, compared to the general population.

## II. What action is the Agency taking?

Under section 5 of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), 7 U.S.C. 136c, EPA can allow manufacturers to field test pesticides under development. Manufacturers are required to obtain an EUP before testing new pesticides or new uses of pesticides if they conduct experimental field tests on 10 acres or more of land or one acre or more of water. A copy of the applications and any information submitted is available for public review in the docket established for these EUP applications.

Following the review of the application and any comments and data received in response to this solicitation, EPA will decide whether to issue or deny the EUP request, and if issued, the conditions under which it is to be conducted. Any issuance of an EUP will be announced in the **Federal Register**.

Therefore, pursuant to 40 CFR 172.11(a), the Agency has determined that the following EUP applications may be of regional and national significance, and therefore is seeking public comment on the following EUP applications:

1. *524-EUP-RNA.* (EPA-HQ-OPP-2013-0012). *Submitter:* Monsanto Company, 800 N. Lindbergh Blvd., St. Louis, MO 63167. *Pesticide chemical:* MON 102100. *Type of chemical:* Nematicide. *Summary of request:* Large scale seed treatment trials on corn, soybean, and cotton. 12.94 pounds (lb.) of active ingredient (a.i.) per year on corn seed, 19.10 lb. of a.i. per year on soybeans seed, and 7.46 lb. of a.i. per year on cotton seed will be used in 208 locations of 20 ft. x 1,000 ft. plots. Period of treatment is from February 1, 2014, to December 31, 2016. Treated seed must be dyed to impart an unnatural color to prevent use for food, feed, or oil purposes. This is a crop-destruct EUP.

2. *72500-EUP-E.* (EPA-HQ-OPP-2013-0546). *Submitter:* Scimetrix Ltd. Corp., P.O. Box 1045, Wellington, CO 80549. *Pesticide chemical:* Warfarin. *Type of chemical:* Rodenticide. *Summary of request:* Authorization requested to use 0.005% warfarin bait blocks at one or more test sites in large, fenced areas in Texas. 0.63 lb of warfarin in 12,600 lb of formulated bait. Bait to be applied on 25 lb to 100 lb amounts in dispensers said to allow feral hogs to access bait while limiting access by nontarget species. Area covered by treatments not to exceed 2,471 acres (10 km<sup>3</sup>). Baiting period is projected to last 3 weeks, with dispensers being replenished "as needed." Proposed period of treatment is from July 1, 2014, to August 31, 2014.

### List of Subjects

Environmental protection, Experimental use permits.

Dated: September 23, 2013.

**Daniel J. Rosenblatt,**

*Acting Director, Registration Division, Office of Pesticide Programs.*

[FR Doc. 2013-23947 Filed 10-1-13; 8:45 am]

**BILLING CODE 6560-50-P**

## FEDERAL FINANCIAL INSTITUTIONS EXAMINATION COUNCIL

[Docket No. AS13-22]

### Appraisal Subcommittee Meeting

**AGENCY:** Appraisal Subcommittee of the Federal Financial Institutions Examination Council.

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with Section 1104(b) of Title XI of the Financial Institutions Reform, Recovery, and Enforcement Act of 1989, as amended, notice is hereby given that the Appraisal Subcommittee (ASC) will meet in open session for its regular meeting:

**DATES:** October 9, 2013.

**ADDRESSES:** 400 7th Street SW., Washington, DC 20024.

**SUPPLEMENTARY INFORMATION:**

Location: OCC—400 7th Street SW., Washington, DC 20024

Date: October 9, 2013

Time: 10:30 a.m.

Status: Open

### Matters To Be Considered

#### Summary Agenda

September 11, 2013 minutes—Open Session

(No substantive discussion of the above items is anticipated. These matters will be resolved with a single vote unless a member of the ASC requests that an item be moved to the discussion agenda.)

#### Discussion Agenda

Appraisal Foundation May, June and July 2013 Grant Reimbursement Requests

Phase 2 Appraisal Complaint Hotline Recommendations  
Mississippi and South Carolina Compliance Reviews

### How To Attend and Observe an ASC Meeting

Email your name, organization and contact information to [meetings@asc.gov](mailto:meetings@asc.gov).

You may also send a written request via U.S. Mail, fax or commercial carrier to the Executive Director of the ASC, 1401 H Street NW., Ste 760, Washington, DC 20005. The fax number is 202-289-4101. Your request must be received no later than 4:30 p.m., ET, on the Monday prior to the meeting. Attendees must have a valid government-issued photo ID and must agree to submit to reasonable security measures. The meeting space is intended to accommodate public attendees. However, if the space will not

accommodate all requests, the ASC may refuse attendance on that reasonable basis. The use of any video or audio tape recording device, photographing device, or any other electronic or mechanical device designed for similar purposes is prohibited at ASC meetings.

Dated: September 26, 2013.

**James R. Park,**

*Executive Director.*

[FR Doc. 2013-23985 Filed 10-1-13; 8:45 am]

**BILLING CODE 6700-01-P**

## FEDERAL FINANCIAL INSTITUTIONS EXAMINATION COUNCIL

[Docket No. AS13-23]

### Appraisal Subcommittee Meeting

**AGENCY:** Appraisal Subcommittee of the Federal Financial Institutions Examination Council.

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with Section 1104(b) of Title XI of the Financial Institutions Reform, Recovery, and Enforcement Act of 1989, as amended, notice is hereby given that the Appraisal Subcommittee (ASC) will meet in closed session:

**DATES:** October 9, 2013.

**ADDRESSES:** 400 7th Street SW., Washington, DC 20024.

**SUPPLEMENTARY INFORMATION:**

*Location:* OCC—400 7th Street SW., Washington, DC 20024

*Date:* October 9, 2013

*Time:* Immediately following the ASC open session

*Status:* Closed

### Matters To Be Considered

September 11, 2013 minutes—Closed Session

Preliminary discussion of State Compliance Reviews

Dated: September 26, 2013.

**James R. Park,**

*Executive Director.*

[FR Doc. 2013-23986 Filed 10-1-13; 8:45 am]

**BILLING CODE 6700-01-P**

## FEDERAL RESERVE SYSTEM

### Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors

that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than October 16, 2013.

A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198-0001:

1. *Glory Burns, Fort Collins, Colorado, Robin Isham, Templeton, California, Andrea Voss, Chadron, Nebraska, Julie Jennings, Lone Tree, Colorado, and R. Will Isham, Gordon, Nebraska,* individually and as trustees of the E. Joy Isham Irrevocable Trust, and the RWI Marital Deduction Testamentary Trust, both of Gordon, Nebraska, all as members of the Isham Family Group, to retain voting shares of Isham Management Company, and thereby indirectly retain voting shares of The First National Bank of Gordon, both in Gordon, Nebraska.

Board of Governors of the Federal Reserve System, September 26, 2013.

**Margaret McCloskey Shanks,**

*Deputy Secretary of the Board.*

[FR Doc. 2013-23936 Filed 10-1-13; 8:45 am]

**BILLING CODE 6210-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Findings of Research Misconduct

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

*Nitin Aggarwal, Ph.D., Medical College of Wisconsin and University of Wisconsin-Madison:* Based on the reports of the investigations conducted by the Medical College of Wisconsin (MCW) and the University of Wisconsin-Madison (UW) and additional analysis conducted by the ORI in its oversight review, ORI found that Dr. Nitin Aggarwal, former Graduate Student, MCW, and former Assistant Scientist, UW, engaged in research misconduct in research supported by National Heart, Lung, and

Blood Institute (NHLBI), National Institutes of Health (NIH), grants R01 HL37981, R01 HL54075, and R01 HL57414.

ORI found that that the Respondent engaged in research misconduct by falsifying and/or fabricating PHS-supported data in six (6) figures that were included in the following two (2) publications, one (1) grant application to the American Heart Association (AHA), one (1) grant application to NIH, and the Respondent's Ph.D. thesis:

- Aggarwal, N.T., Pfister, S.L., & Campbell, W.B. "Hypercholesterolemia Enhances 15-Lipoxygenase Mediated Vasorelaxation and Acetylcholine-Induced Hypotension." *Arteriosclerosis, Thrombosis, and Vascular Biology* 28:2209-2215, 2008 (hereafter the "ATVB paper").

- Aggarwal, N.T., Pfister, S.L., Gauthier, K.M., Chawengsub, Y., Baker, J.E., & Campbell, W.B. "Chronic hypoxia enhances 15-lipoxygenase-mediated vasorelaxation in rabbit arteries." *American Journal of Physiology—Heart Circulation Physiology* 296:H678-H688, 2008 (hereafter the "AJP paper").

- Aggarwal, N.T., Principal Investigator (P.I.), National Scientist Development grant application to the American Heart Association No. 11SDG7650072, "Sulfonylurea rReceptor-2 splice variant and mitochondrial mechanisms for cardioprotection and arrhythmia" (hereafter the "AHA grant application").
- K99 HL113518-01, "Mitochondrial ATP-sensitive K-channels and pharmacological approaches for cardioprotection," Aggarwal, Nitin, Ph.D., P.I.

- Aggarwal, N.T. "Endothelial 15-lipoxygenase regulates vasorelaxation and blood pressure in rabbits in normal and pathological conditions." A Dissertation Submitted to the Faculty of the Graduate School of Biomedical Science of the Medical College of Wisconsin in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy, Milwaukee, Wisconsin, 2008 (hereafter the "thesis").

Specifically, ORI found that Respondent engaged in research misconduct by falsifying Western blot loading control data by inverting, duplicating, and cropping source blot films and/or using films from unrelated experiments to construct five (5) false Western blot figures. In the absence of valid blot images, Respondent falsified and/or fabricated the corresponding quantitative data for summary bar graphs and the data statistics in related text. Respondent admitted to falsely reporting the number of mice reported for an experiment reported in Figure 4